Business divestment announced
As filed · General Updates
What happened
FactDivestment of Equity stake in Texas Lifesciences Private Limited, Subsidiary. on the recommendations of the Audit Committee of the Board, considered and approved the Divestment. of 43.81% equity shareholding out of total 54.81% in its subsidiary, Texas Lifesciences Private Limited.
Why it matters
CapitSignal interpretationSelling a business converts an operating asset into cash; what the cash is then used for decides whether holders benefit.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Guidance
DelayedPreparations for the Avian Influenza vaccine launch remain on track, with the expected roll-out in the second quarter of FY26 poised to further strengthen our portfolio.
we remain confident in achieving breakeven within the next two years, with further profitability gains beyond that.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Sale consideration
- Stated use of proceeds
- Revenue and profit leaving the group
- we remain confident in achieving breakeven within the next two years, with further profitability gains beyond (management committed by FY27)
- Our Fill-Finish facility is on track to be operational by Q2 FY26, and the BSL-3 facility awaits final adminis (management committed by Q2 FY26)
Evidence
- Hester Biosciences Limited has informed the Exchange about Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Divestment of Equity stake in Texas Lifesciences Private Limited, Subsidiary(opens the original filing in a new tab)
- Earlier statement · FY25
- Latest statement · FY25
How CapitSignal classified this
- Reasoning:
- DIVESTMENT base 64; +5 quantified amount; +3 quantified percentage; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%